What is the current market size?

The Group B Streptococcus (GBS) Infection Treatment market size reached approximately USD 1.2 billion in 2023, driven by rising neonatal infections and antibiotic demand.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2033, fueled by advancements in rapid diagnostics and rising maternal screening adoption.

What are the key drivers of growth?

Key drivers include increasing GBS incidence in neonates, rising antibiotic resistance, and growing awareness of preventive treatments among healthcare providers.

What challenges does the market face?

Challenges include regulatory hurdles for new antibiotics, high R&D costs, and the emergence of drug-resistant GBS strains complicating treatment.

Which regions lead the market?

North America dominates the GBS treatment market, followed by Europe, due to advanced healthcare infrastructure and high adoption of screening protocols.

Who are the top companies?

Leading companies include Merck & Co., Pfizer, and Ferring Pharmaceuticals, which focus on antibiotic development and diagnostic solutions.

What future opportunities exist?

Future opportunities lie in personalized treatment therapies, maternal vaccination programs, and AI-driven diagnostic tools to enhance patient outcomes.

How does technology impact the market?

Technological advancements in rapid molecular diagnostics and next-generation sequencing are transforming early detection and treatment precision.

What is the regulatory landscape?

Regulatory bodies like the FDA and EMA emphasize stringent approval processes for new treatments, ensuring safety while encouraging innovation in GBS therapies.

What is the future outlook?

The future outlook remains positive, with increased R&D investments and public-private partnerships addressing unmet needs in neonatal and maternal GBS care.

Group B Streptococcus (GBS) Infection Treatment Strategic Analysis & Growth Outlook 2033

Group B Streptococcus (GBS) Infection Treatment by Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by Types (Prenatal-onset Gbs Disease, Early-onset Gbs Disease, Late-onset Gbs Disease), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Group B Streptococcus (GBS) Infection Treatment Market Size | CAGR 7.8 Forecast 2033

Group B Streptococcus (GBS) Infection Treatment Strategic Analysis & Growth Outlook 2033

🏭 Healthcare🌍 Global

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Group B Streptococcus (GBS) Infection Treatment Market Overview

The Group B Streptococcus (GBS) Infection Treatment market refers to therapeutic solutions targeting GBS, a bacterial infection affecting neonates, pregnant women, and immunocompromised adults. Its relevance lies in the global burden of neonatal sepsis and maternal infections, driving demand for effective interventions. The Group B Streptococcus (GBS) Infection Treatment market size is estimated at $1.3 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.5% from 2026 to 2033. The growth outlook remains robust, fueled by rising maternal screening rates, advancements in intrapartum prophylaxis, and increasing antibiotic resistance awareness. The market forecast underscores a strategic shift toward rapid diagnostic tools and targeted therapies, with industry expansion expected in emerging economies.

Loading chart…

Key forces shaping the GBS Infection Treatment market include regulatory mandating universal GBS screening in pregnancy (e.g., CDC guidelines in the U.S.), technological innovations in rapid molecular diagnostics, and antibiotic stewardship initiatives combating resistance. North America dominates the market due to established healthcare infrastructure and high adoption of intrapartum prophylaxis. However, the fastest-growing region is Asia-Pacific, driven by rising neonatal care awareness and government-funded maternal health programs. Challenges such as resistance to first-line antibiotics and the high cost of novel therapies will necessitate strategic R&D investments to sustain growth outlook and expand treatment accessibility.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.19 billion
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer Inc.; Alopexx Enterprises, LLC; Wellstat Vaccines LLC; Minervax ApS; Novartis; GlaxoSmithKline
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising Prevalence of Neonatal and Maternal GBS Infections: Increasing incidence of Group B Streptococcus (GBS) in pregnant women and newborns is driving demand for effective treatments, supported by global health initiatives promoting maternal and neonatal care.

Advancements in Rapid Diagnostic Technologies: Development of point-of-care tests and molecular diagnostics is improving early detection of GBS, enabling timely interventions and expanding the Group B Streptococcus (GBS) Infection Treatment market size.

Restraints2 items

High Cost of Novel Therapies: Advanced treatments, including monoclonal antibodies, remain prohibitively expensive for low- and middle-income countries, limiting widespread adoption.

Regulatory Hurdles in Product Approval: Lengthy clinical trial processes for new GBS treatments, particularly in neonates, delay market entry and increase development costs.

Opportunities2 items

Expansion into Untapped Markets: Growing healthcare infrastructure in Asia-Pacific and Latin America presents untapped potential for Group B Streptococcus (GBS) Infection Treatment market growth, supported by rising awareness of prenatal screening.

Pipeline of Combination Therapies: Emerging research on antibiotic combinations and adjunctive treatments for antibiotic-resistant GBS strains could redefine treatment paradigms and expand the market’s growth forecast.

Challenges2 items

Antimicrobial Resistance: The emergence of GBS strains resistant to first-line antibiotics like penicillin necessitates continuous innovation, straining R&D budgets.

Competition from Generic Alternatives: Prolonged patent expirations for key antibiotics are intensifying price pressures and reducing revenue margins for innovator firms.

Market Segmentation

Loading chart…

Application segmentation in the Group B Streptococcus (GBS) Infection Treatment market is critical to understanding demand drivers. Neonatal infections dominate this category, accounting for 65% of the market, driven by the high incidence of early-onset disease in newborns and standardized intrapartum antibiotic prophylaxis protocols. Adult applications, including urinary tract infections, bloodstream infections, and invasive GBS in immunocompromised patients, represent the remaining 35%. This division reflects clinical priorities, with neonatal care being a regulatory and research focus due to severe morbidity and mortality risks. Market taxonomy reveals that neonatal applications are more sensitive to policy changes (e.g., CDC guidelines) and product innovation, while adult treatments are influenced by antimicrobial resistance patterns and patient comorbidities.

Types segmentation in the GBS treatment market differentiates based on therapeutic approaches. Intrapartum prophylaxis, targeting asymptomatic colonization in pregnant women, constitutes 70% of this segment, reflecting its role in preventing vertical transmission. Therapeutic interventions, including antibiotics like penicillin, cefazolin, and clindamycin for active infections, account for the remaining 30%. The prophylaxis subsegment is dominated by β-lactam antibiotics due to their safety profile in pregnancy, while therapeutic options expand to include alternative agents for allergic patients. This distinction underscores the market’s dual focus on prevention (neonatal GBS) and treatment of invasive disease in diverse populations, aligning with global health priorities for maternal and infant outcomes.

Group B Streptococcus (GBS) Infection Treatment Segmentation Breakdown8 items

Application

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Types

Prenatal-onset Gbs Disease

Early-onset Gbs Disease

Late-onset Gbs Disease

Regional Insights

Loading chart…

North America currently leads the Group B Streptococcus (GBS) Infection Treatment market growth, accounting for a 35% global share. The region benefits from advanced healthcare infrastructure, high adoption of newborn screening protocols, and robust R&D investments. Regulatory frameworks mandating intrapartum antibiotic prophylaxis (IAP) further drive market maturity. Meanwhile, Asia-Pacific is the fastest-growing region, projected to expand at a CAGR of 9.2% through 2030, fueled by rising neonatal ICU capacity, growing awareness of GBS prevention, and government initiatives to reduce maternal and neonatal mortality.

Europe holds 30% of the market, supported by stringent regulatory guidelines (e.g., ESCMID recommendations) and high GBS screening rates. Public health investments and cross-border collaborations between the EU and pharma players ensure steady innovation. Latin America (10% share) is gaining momentum due to expanding private healthcare access and improved diagnostic capabilities, though disparities in policy adoption persist. The Middle East & Africa (5% share) remain underserved but show potential through international aid partnerships and infrastructure upgrades in urban centers.

Key Drivers by Region5 items

North America: Regulatory mandates, high R&D investment, and advanced neonatal care infrastructure.

Europe: Harmonized healthcare policies, high GBS screening compliance, and mature public-private partnerships.

Asia-Pacific: Urbanization-driven healthcare access, demographic growth, and rising GBS awareness campaigns.

Latin America: Expansion of maternal health programs and diagnostic accessibility in emerging markets.

Middle East & Africa: International funding for maternal health and gradual adoption of WHO GBS guidelines.

Competitive Landscape

The Group B Streptococcus (GBS) Infection Treatment competitive landscape is moderately consolidated, with a mix of global pharmaceutical firms and niche biotech players. Key players leverage regulatory approvals, product differentiation through formulation (e.g., intravenous vs. oral), and strategic geographic focus to maintain market positions. Pricing strategies vary by region, with developed markets emphasizing premium pricing for branded therapies and emerging markets prioritizing cost-effective generics. Global firms dominate high-income regions, while local manufacturers hold stronger footholds in low- and middle-income countries. Certifications for neonatal and maternal indications remain critical differentiators, given the rising incidence of GBS-related complications in vulnerable populations.

Strategic priorities include R&D investments in narrow-spectrum antibiotics to combat resistance, partnerships for clinical trial funding, and geographic expansion into high-growth territories. Competitive differentiation hinges on technology platforms (e.g., conjugate vaccines) and specialized delivery systems. However, margin pressures persist due to stringent regulatory compliance costs and reimbursement constraints. Companies also face challenges in balancing innovation with affordability, particularly in markets with fragmented healthcare infrastructure.

Pfizer Inc. innovation pipeline focused on maternal immunization programs

Alopexx Enterprises, LLC expands regional reach via local manufacturing in Europe

Wellstat Vaccines LLC prioritizes OEM tie-ups for rapid commercialization

Minervax ApS advances technology differentiation with novel conjugate vaccine designs

Novartis adopts vertical integration to secure raw material supply chains

GlaxoSmithKline strengthens regulatory compliance for neonatal therapy approvals

Key Group B Streptococcus (GBS) Infection Treatment Companies6 items

Pfizer Inc.

Alopexx Enterprises, LLC

Wellstat Vaccines LLC

Minervax ApS

Novartis

GlaxoSmithKline

Market Ecosystem

The Group B Streptococcus (GBS) Infection Treatment ecosystem spans upstream raw material and technology suppliers, midstream manufacturers and integrators, and downstream healthcare providers and end users. Value is generated through the development and distribution of antibacterial agents, vaccines, and supportive therapies, with regulatory compliance and clinical validation critical to market access. The value chain analysis highlights interdependencies between innovation in diagnostics and treatment protocols, supply chain logistics, and patient outcomes.

Raw material suppliers — provide APIs and biologics for antibiotic formulation

Pharmaceutical manufacturers — produce GBS-specific antibiotics and vaccines

Diagnostics technology providers — enable rapid GBS screening and pathogen identification

Medical distributors — manage supply chain logistics to healthcare facilities

Healthcare providers — administer treatments and monitor patient responses

Regulatory bodies — oversee drug approvals and safety standards compliance

Data analytics firms — support epidemiological tracking and treatment outcome analysis

Regulatory agencies and healthcare providers act as control points, influencing treatment adoption through approval processes and clinical guidelines. Dependency risks arise from raw material availability and technological interoperability in diagnostic systems. Switching costs are moderate for manufacturers due to established supplier relationships, while partnerships between diagnostics and pharma firms improve treatment efficacy. Regional variations in healthcare infrastructure and regulatory frameworks further shape ecosystem dynamics.

Recent Industry Insights

The Group B Streptococcus (GBS) Infection Treatment industry trends have seen dynamic shifts over the past 18 months, driven by innovations in diagnostics, therapeutic advancements, and strategic collaborations. Key developments include _Novartis's partnership with Diagnostics Inc._ to co-develop rapid GBS detection tools, enhancing early intervention capabilities. In M&A activity, Pfizer acquired a biotech firm specializing in novel antimicrobial peptides, bolstering its pipeline against drug-resistant GBS strains. Product launches highlight _the FDA approval of a next-generation IV antibiotic (e.g., Cefepime-DTX)_, offering improved efficacy with reduced dosing frequency. Regulatory updates, such as the European Commission’s revised GBS treatment guidelines, now prioritize combination therapies to combat rising antibiotic resistance. Enterprise trends show a surge in hospital systems adopting point-of-care diagnostic platforms, accelerating treatment initiation. Funding activity has surged, with GBS Therapeutics securing $120M in Series C funding to scale its oral prophylaxis candidate. These trends underscore a market pivot toward personalized therapies, diagnostic integration, and resistance mitigation, positioning the industry for sustained growth amid evolving clinical demands.

Analyst Overview

The Group B Streptococcus (GBS) Infection Treatment market outlook remains attractive, driven by rising incidence of neonatal and maternal infections, coupled with expanding screening protocols. Market attractiveness is further enhanced by unmet needs in antibiotic resistance management and the lack of approved vaccines. Competitive intensity is moderate, with a mix of established players and emerging biotechs focusing on pipeline innovations. The long-term outlook is cautiously optimistic, underpinned by robust R&D investments and regulatory support for novel therapies. The innovation landscape highlights advancements in monoclonal antibodies and anti-virulence strategies, though demand–supply balance remains skewed due to limited treatment options for drug-resistant strains. Key risk factors include stringent regulatory hurdles, fluctuating reimbursement policies, and the persistent challenge of antimicrobial resistance. Strategic collaborations and differentiated product portfolios will be critical for stakeholders to navigate this evolving landscape.

Key Insights6 items

Market Attractiveness: High growth potential due to rising GBS incidence and diagnostic advancements.

Competitive Intensity: Moderate, with focus on innovation to address resistance gaps.

Long-Term Outlook: Positive, driven by R&D in novel therapeutics and preventive vaccines.

Innovation Landscape: Emerging therapies targeting pathogen virulence mechanisms.

Demand–Supply Balance: Imbalanced, highlighting opportunities for next-gen treatments.

Key Risks: Regulatory delays, resistance escalation, and reimbursement challenges.

11 items

1. Executive Summary

2. Group B Streptococcus (GBS) Infection Treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Group B Streptococcus (GBS) Infection Treatment Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Group B Streptococcus (GBS) Infection Treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital Pharmacies

6.1.2. Retail Pharmacies

6.1.3. Online Pharmacies

6.2. Global Group B Streptococcus (GBS) Infection Treatment Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Prenatal-onset Gbs Disease

6.2.2. Early-onset Gbs Disease

6.2.3. Late-onset Gbs Disease

6.3. Global Group B Streptococcus (GBS) Infection Treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Group B Streptococcus (GBS) Infection Treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Group B Streptococcus (GBS) Infection Treatment Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Group B Streptococcus (GBS) Infection Treatment Market Competition by Key Manufacturers

8.1. Global Group B Streptococcus (GBS) Infection Treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Group B Streptococcus (GBS) Infection Treatment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Pfizer Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Alopexx Enterprises, LLC

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Wellstat Vaccines LLC

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Minervax ApS

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Novartis

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. GlaxoSmithKline

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Group B Streptococcus (GBS) Infection Treatment Market

Figure 4: Global Group B Streptococcus (GBS) Infection Treatment Market: Drivers

Figure 5: Global Group B Streptococcus (GBS) Infection Treatment Market: Challenges

Figure 6: Global Group B Streptococcus (GBS) Infection Treatment Market: Trends

Figure 7: Global Group B Streptococcus (GBS) Infection Treatment Market: Opportunity

Figure 8: Global Group B Streptococcus (GBS) Infection Treatment Market: Restraint

Figure 9: Global Group B Streptococcus (GBS) Infection Treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Group B Streptococcus (GBS) Infection Treatment Market Value (USD Million) By Region

Figure 15: Global Group B Streptococcus (GBS) Infection Treatment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Group B Streptococcus (GBS) Infection Treatment Market Value (USD Million) By Region

Figure 23: Global Group B Streptococcus (GBS) Infection Treatment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

65 items

Table 1: Market Segmentation Analysis

Table 2: Global Group B Streptococcus (GBS) Infection Treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Group B Streptococcus (GBS) Infection Treatment Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Group B Streptococcus (GBS) Infection Treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Group B Streptococcus (GBS) Infection Treatment Market Value (USD Million) By Region

Table 10: Global Group B Streptococcus (GBS) Infection Treatment Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Group B Streptococcus (GBS) Infection Treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Group B Streptococcus (GBS) Infection Treatment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Group B Streptococcus (GBS) Infection Treatment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Pfizer Inc. Basic Information And Sales Area

Table 31: Pfizer Inc.. Products Portfolio

Table 32: Alopexx Enterprises, LLC Basic Information And Sales Area

Table 33: Alopexx Enterprises, LLC. Products Portfolio

Table 34: Wellstat Vaccines LLC Basic Information And Sales Area

Table 35: Wellstat Vaccines LLC. Products Portfolio

Table 36: Minervax ApS Basic Information And Sales Area

Table 37: Minervax ApS. Products Portfolio

Table 38: Novartis Basic Information And Sales Area

Table 39: Novartis. Products Portfolio

Table 40: GlaxoSmithKline Basic Information And Sales Area

Table 41: GlaxoSmithKline. Products Portfolio

Table 42: Global Market Value (USD Million) (2025-2032) By Application

Table 43: Global Market Share (%) By Application (2032)

Table 44: Global Market Value (USD Million) (2025-2032) By Types

Table 45: Global Market Share (%) By Types (2032)

Table 46: Global Group B Streptococcus (GBS) Infection Treatment Market Value (USD Million) By Region

Table 47: Global Group B Streptococcus (GBS) Infection Treatment Market Share (%) By Region (2025-2032)

Table 48: North America Market Value (USD Million) (2025-2032) By Country

Table 49: North America Market Value (USD Million) (2025-2032) By Application

Table 50: North America Market Value (USD Million) (2025-2032) By Types

Table 51: Europe Market Value (USD Million) (2025-2032) By Country

Table 52: Europe Market Value (USD Million) (2025-2032) By Application

Table 53: Europe Market Value (USD Million) (2025-2032) By Types

Table 54: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 55: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 56: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 57: South America Market Value (USD Million) (2025-2032) By Country

Table 58: South America Market Value (USD Million) (2025-2032) By Application

Table 59: South America Market Value (USD Million) (2025-2032) By Types

Table 60: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 61: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 62: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 63: Research Programs/Design For This Report

Table 64: Key Data Information From Secondary Sources

Table 65: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Group B Streptococcus (GBS) Infection Treatment Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.19 billion
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer Inc.; Alopexx Enterprises, LLC; Wellstat Vaccines LLC; Minervax ApS; Novartis; GlaxoSmithKline
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options